The green index is a reference tool created in 2012 by the CAHPP which measures the sustainable commitment of suppliers to healthcare establishments. The Provepharm teams are happy to have obtained the label's A mention for the first time this year.
Provepharm will participate for the first time in the National Training Days on medical devices organized by Euro-pharmat, which will be held in La Rochelle from October 4 to 6, 2022.
For the third consecutive year, Provepharm will participate in the "Convergences Santé Hôpital" Meetings, which will take place from September 13 to 16, 2022 at the Neptune Convention Center in Toulon.
Our CSR report, published for seven years on the Global Compact website, has become an essential medium for promoting our voluntary and ambitious approach to all of our stakeholders.
Provepharm receives FDA approval for BLUDIGO™ (indigotindisulfonate sodium, USP) Injection
Act to improve life.
Act is the commitment tomobilize our resources to achieve our mission.
Act is daring to refuse the status quo and to define new standards of innovation.